I was born and raised in New York City, so I have always had an appreciation for NYU Langone and NYC Health + Hospitals/Bellevue. In addition to providing care for people who have cancer, I am a breast cancer survivor and was treated at NYU Langone. Because of my experiences, I have a better understanding of how to meet my patients’ needs.
As a hematologist and oncologist, I provide care to people who have cancers of the blood, including leukemia, lymphoma, and myelodysplastic syndromes (MDS). In 2004, I became the director of the Bellevue Cancer Center and was tasked with overseeing medical and surgical oncology at Bellevue, while providing seamless referral services for radiation oncology, bone marrow transplants, and genetic counseling to Perlmutter Cancer Center.
Additionally, I helped develop a multilingual patient navigation program and educational programs for patients and caregivers in English, Spanish, and Mandarin. I also helped initiate community outreach efforts, as well as interactive clinics and meetings that allow for collaboration between different specialties.
I believe that good care requires a strong partnership between patients and physicians. I aim to provide curative and palliative treatments that are in keeping with people’s own goals of care, always respecting their cultural and religious beliefs. Additionally, I participate in clinical trials so that my patients have access to new therapies.
I am a fellow of the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, and the International Society on Thrombosis and Haemostasis. I am also the recipient of NYU School of Medicine’s hematology and oncology teaching award.
Conditions and Treatments
- hematologic malignancies
biomolecular significance of thrombin receptors on tumor cells, hematologic malignancies, health care disparaties, outcomes research
Metastatic cancer is associated with a hypercoagulable state; tumor cells can generate thrombin on their surface. We study the biomolecular significance of thrombin receptors on tumor cells. Platelets are required for metastasis in vivo. We showed that treating platelets with thrombin enhanced the adhesion of naive tumor cells to platelets. Active thrombin was necessary on the platelet surface. Thrombin administration with murine tumor cells enhanced pulmonary metastasis via a tail-vein injection in syngeneic mice. The platelet GPIIb-lIla adhesive ligand receptor was important for platelet-tumor cell interaction in vitro and metastasis in vivo.
A unique seven-membrane spanning thrombin receptor was cloned by Vu and colleagues in 1991 which requires proteolysis to produce a tethered ligand capable of activating the thrombin receptor. The thrombin receptor activation peptide (TRAP) from the tethered end recapitulated the thrombin effect on transfected xenopus oocytes and human platelets. We demonstrated the presence of the cloned receptor by RT-PCR in human and murine tumor cells lines and human tumor samples. Thrombin or TRAP treatment of tumor cells supported enhanced adhesion to platelets and increased murine metastasis in syngeneic mice
Currrently were are developing clinical trials to assess the use of antithrombin agents as adjuvants to chemotherapy.
A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)
Journal of cutaneous pathology. 2012 Nov ; 39(11):1026-9
Journal of oncology practice. 2011 Jan ; 7(1):31-8
Investigational new drugs. 2010 Oct ; 28(5):670-6